BACKGROUND: Radiosensitivity by blocking the epidermal growth factor receptor and
cyclooxygenase-2 pathways with erlotinib and celecoxib in A549 human lung cancer cell …

Purpose Radioresistance is highly correlated with radiotherapy failure in clinical cancer
treatment. In the current study, we sought to examine the efficacy of Celecoxib and Afatinib …

The current study aimed to identify the radiosensitizing effect of celecoxib, a selective
cyclooxygenase-2 (COX-2) inhibitor, in combination with radiotherapy in non-small-cell lung …

Purpose: To characterize the radiation-enhancing effects and underlying mechanisms of
combined treatment with celecoxib, a cyclooxygenase-2 selective inhibitor, and gefitinib, an …

Radiotherapy resistance is an enduring major setback in lung cancer therapy, and is
responsible for a large proportion of treatment failures. In previous years, cyclooxygenase‑2 …

Objective To explore the radiosensitizing effect of erlotinib on human lung adenocarcinoma
cell line A549 cells and the related mechanisms. Methods The inhibitory effect of erlotinib on …

Background: Previous work has proposed that celecoxib may be able to enhance the effects
of radiotherapy. However, the underlying mechanism of this activity has not yet been …

Targeting epidermal growth factor receptor (EGFR) is a promising approach to increasing
radiosensitivity of head and neck cancers but treatment resistance remains an important …

To characterize the radiation-enhancing effects on human cancer cells and underlying
mechanisms of celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, and to ascertain …

Abstract Purpose: Cyclooxygenase (COX)-2 up-regulation plays an important role in the
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …